Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEX: Bromfenac for Postoperative Inflammation in Pseudoexfoliation Syndrome Cataract Surgery
NCT02137161Phase 4Completed
- Sponsor
- Azienda USL-IRCCS di Reggio Emilia
- Start
- Nov 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bromfenac sodium in cataract, pseudoexfoliation syndrome (PXF), sponsored by Azienda USL-IRCCS di Reggio Emilia. Started Nov 2013; status: completed.
02
Drugs
bromfenac sodium
03
Conditions
cataractpseudoexfoliation syndrome (PXF)
Beyond the preview
Go deeper on NCT02137161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137161.